Effect of BMS-914392 on Pharmacokinetics of Metoprolol

Completed · Phase 1

Conditions studied: Atrial Fibrillation

In brief

The purpose of the study is to assess the effects of BMS-914392 administration on the pharmacokinetics of a single-dose of metoprolol in healthy subjects.

Key facts

Study ID

NCT01211821

Run by

Bristol-Myers Squibb

People needed

18

Starts

2010-09-01

Expected to finish

2010-11-01

Last updated by the study team

2011-02-02

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.
• Subjects genotyped as Intermediate, Extensive or Ultra-rapid CYP2D6 metabolizers
• Women of childbearing potential (WOCBP) and men must be using an acceptable method of contraception to avoid pregnancy

You may not qualify if…

• Any significant acute or chronic medical illness.
• Current or recent (within 3 months of study drug administration) gastrointestinal disease.
• Current or history of neurological diseases or psychiatric disorders, cardiovascular diseases, and bronchospastic diseases.
• CYP2D6 poor metabolizers based on genotype

Where it is running

• Pra International — Lenexa, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.